Persistence of Biological Treatment and Inhibitors of Jak Kinases in Patients With Rheumatoid Arthritis.

Persistence of Biological Treatment and Inhibitors of Jak Kinases in Habitual Clinical Practice in Patients With Rheumatoid Arthritis. Influence of the Comorbidities.

One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb).

These patients will be administered a series of medications and a follow-up will be carried out to analyze their evolution.

One-center observational study aimed at determining the survival of patients with rheumatoid arthritis treated with targeted synthetic disease-modifying drugs (FAMEsd) and biologic disease-modifying drugs (FAMEb).

The drugs to be administered to patients are:

• JAK-type kinase inhibitors.
• Monoclonal antibodies against TNF.
• Soluble receptor against TNF.
• Biosimilar FAMEb.
• Rituximab.
• Abatacept.
• Drugs that block IL6.

A follow-up will be carried out at 12, 24, 48, 60, 72 and 84 months from the start of treatment, to analyze how the patient's health improves.

Inclusion Criteria:

• Patients aged ≥18 years.
• With a diagnosis of Adult Rheumatoid Arthritis according to the 2010 ACR / EULAR criteria.
• Who have received at least one of the doses of the study drugs.
• In follow-up in the consultations of the UGC of Rheumatology of the HUVM.
• With at least two complete evaluations (baseline and final) of clinical variables.

Exclusion Criteria:

• Patients where the medical records lack sufficient baseline and final variables to perform the analysis.
• Patients in whom more than 50% of the variables to be collected are missing in the data collection.